Pharma Cos Vs. The Common Man: Whom Will the TPP Pact Choose?

It was only recently that the world hailed India’s decision against granting a cancer drug patent to medico giant Novartis, ensuring that cost-effective medication is available to the masses. Following suit, several nations have shammed some portions of the trade agreement IPR text mentioned in the Trans-Pacific agreement, says a new Wikileaks report. Now, can patenting be a bane is a question that comes to the fore. Cancer Immunotherapy: Antibody Therapy U.S. Patent Landscape Report. Bristol-Myres Read more [...]

Post a Comment

Your email address will not be published. Required fields are marked *